» Articles » PMID: 33080466

WNT/β-catenin Signaling in the Development of Liver Cancers

Overview
Date 2020 Oct 20
PMID 33080466
Citations 145
Authors
Affiliations
Soon will be listed here.
Abstract

The WNT/β-catenin signaling pathway is a highly conserved and tightly controlled molecular mechanism that regulates embryonic development, cellular proliferation and differentiation. Of note, accumulating evidence has shown that the aberrant of WNT/β-catenin signaling promotes the development and/or progression of liver cancer, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), the two most prevalent primary liver tumours in adults. There are two different WNT signaling pathways have been identified, which were termed non-canonical and canonical pathways, the latter involving the activation of β-catenin. β-catenin, acting as an intracellular signal transducer in the WNT signaling pathway, is encoded by CTNNB1 and plays a critical role in tumorigenesis. In the past research, most liver tumors have mutations in genes encoding key components of the WNT/β-catenin signaling pathway. In addition, several of other signaling pathways also can crosswalk with β-catenin. In this review, we discuss the most relevant molecular mechanisms of action and regulation of WNT/β-catenin signaling in the development and pathophysiology of liver cancers, as well as in the development of therapeutics.

Citing Articles

CGREF1 facilitates the cell proliferation, migration and invasion of hepatocellular carcinoma cells via regulation of EIF3H/ Wnt/β-Catenin signaling axis.

Gao D, Zhou Z, Chen L, Zheng J, Yang J BMC Cancer. 2025; 25(1):435.

PMID: 40069645 PMC: 11895259. DOI: 10.1186/s12885-025-13808-7.


inhibits liver cancer the Wnt/β-catenin pathway.

Chen J, Lan X World J Gastroenterol. 2025; 31(9):99459.

PMID: 40061585 PMC: 11886046. DOI: 10.3748/wjg.v31.i9.99459.


IGF1R activates FOXP3-β-catenin signaling to promote breast cancer development.

Li L, Zhang Z, Huang N, Ren J, Qin Y, Luo Y Breast Cancer Res Treat. 2025; .

PMID: 40055251 DOI: 10.1007/s10549-025-07663-0.


Metabolic reprogramming in hepatocellular carcinoma: mechanisms and therapeutic implications.

Park S, Hall M Exp Mol Med. 2025; .

PMID: 40025169 DOI: 10.1038/s12276-025-01415-2.


Recent Issues in the Development and Application of Targeted Therapies with Respect to Individual Animal Variability.

Kurhaluk N, Tkaczenko H Animals (Basel). 2025; 15(3).

PMID: 39943214 PMC: 11815764. DOI: 10.3390/ani15030444.